You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Natera has focused on tapping into the average risk market for its suite of noninvasive prenatal assays, which it said is paying off.
The company's revenues were driven by sales of its Panorama NIPT and Horizon carrier screening tests.
Roche said it will offer the microarray-based Harmony IVD kit and Ariosa Cell-Free DNA System (AcfS) software to laboratories outside the US.
The researchers also plan to analyze how payors make coverage decisions for NGS-based gene panels, exome, and whole-genome sequencing clinical tests.
Despite recent bills that argue the advent of NIPS will increase abortion, researchers say that there is not yet enough data.
The findings, published last week, have prompted Belgian medical genetics centers to routinely report maternal incidental findings from NIPT.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
Last week, the G-BA, a committee that decides about reimbursable medical services in Germany, said it will start a methods evaluation of noninvasive prenatal testing.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
The company said it planned to launch version 3 of Panorama this year during a conference call discussing its second quarter 2016 performance.